Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
August 26 2024 - 8:00AM
Business Wire
Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter
M. Fasolo will retire from his position as Executive Vice
President, Chief Human Resources Officer at the end of this year,
following 16 years of leadership and service to the Company.
Throughout his distinguished career, Dr. Fasolo has worked with the
organization’s Board of Directors and partnered with three company
CEOs to shape and grow the Company’s human capital strategy.
He will be succeeded in this role by Kristen Mulholland, a
strong Credo-based leader who has had an exceptional career with
depth and breadth across the Company’s Innovative Medicine and
MedTech sectors, managed business unit HR for the Company’s global
corporate functions, and has led Corporate HR Services including
Performance and Development and most recently Global Total Rewards.
Ms. Mulholland will also be appointed as a member of Johnson &
Johnson’s Executive Committee, effective October 1, 2024. Dr.
Fasolo and Ms. Mulholland will work together during a transition
period until Dr. Fasolo’s retirement at the end of this year.
“Peter has led J&J’s talent strategy for the past 16 years
including remarkable leadership through the global pandemic and the
separation of our consumer health business,” said Joaquin Duato,
Chairman and Chief Executive Officer, Johnson & Johnson.
“Throughout his career, Peter has always led with two principles in
the forefront of every decision and recommendation – Our Credo
values and a deep responsibility to our employees. He leaves a
legacy of strong leaders, deep bench strength and an inclusive,
caring and patient-focused culture.”
Dr. Fasolo first joined Johnson & Johnson in 2004 as
Worldwide Vice President, Human Resources in the MedTech segment.
He also served as the Company’s Chief Talent Officer with
responsibility for executive assessment and development. Dr. Fasolo
became J&J’s CHRO and a member of the Executive Committee in
2010 and has transformed the HR function’s talent and leadership
strategy. During his tenure, he strengthened the Company’s global
Diversity, Equity & Inclusion outcomes and expanded employee
benefits and policies by increasing paid time off for leaves such
as military, parental, bereavement, volunteerism and mental
well-being, and promoted a healthy workforce. In recognition of his
contributions to the Human Resources profession and commitment to
the well-being of our employees, Dr. Fasolo was named a National
Academy Human Resources Fellow in 2017 and Human Resource
Executive’s HR Executive of the Year in 2022.
Kristen Mulholland has been with Johnson & Johnson since
2005. Ms. Mulholland has held HR leadership positions in the
Company’s corporate services, global functions and the MedTech and
Innovative Medicines sectors across commercial and R&D and
helped establish the Company’s Innovation Centers. In her most
recent role as Head of Human Resources, Global Total Rewards &
Enterprise HR Functions at Johnson & Johnson, Ms. Mulholland
worked closely with the Board of Directors supporting the
Compensation & Benefits Committee and played a key role in the
separation of the consumer business to form Kenvue.
“I’m pleased to appoint Kristen to this important role where she
will apply her deep business acumen, talent expertise and
Credo-based approach to advance J&J’s culture and operating
model,” said Mr. Duato. “I’m confident her breadth of experience
and strong leadership will ensure Johnson & Johnson’s human
capital strategy is poised to deliver the innovative future-ready
talent and culture needed to advance healthcare solutions for
patients worldwide.”
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our
strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where
treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech,
we are uniquely positioned to innovate across the full spectrum of
healthcare solutions today to deliver the breakthroughs of
tomorrow, and profoundly impact health for humanity. Learn more at
https://www.jnj.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240826152368/en/
Media: Joshina Kapoor media-relations@its.jnj.com
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2023 to Oct 2024